Induction of apoptosis in hematological cancer cells by dorsomorphin correlates with BAD upregulation

Biochem Biophys Res Commun. 2020 Feb 12;522(3):704-708. doi: 10.1016/j.bbrc.2019.11.157. Epub 2019 Nov 28.

Abstract

AMPK is generally a tumor suppressor. However, once cancer arises, AMPK becomes a tumor promoter instead, driving cancer development. For such AMPK-driven cancers, AMPK blockade may be a valuable therapeutic strategy. Here we show that AMPK is upregulated in a variety of hematological cancers and plays key roles in maintaining viability of tumor cells. Blockade of AMPK signaling by dorsomorphin markedly induces apoptosis in Jurkat, K562 cell lines as well as primary cancerous B cells. Mechanistically, dorsomorphin significantly upregulates the expression of BAD, a pro-apoptotic member of the Bcl-2 gene family involved in initiating apoptosis. Reduction of BAD expression by RNA interference prevents apoptosis in response to AMPK inhibition. Thus, our data found BAD integrates the pro-apoptotic effects of dorsomorphin and provided novel insights into the mechanisms by which AMPK facilitates survival signaling in hematologic tumor cells.

Keywords: AMPK; Apoptosis; Dorsomorphin; Hematological cancers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / antagonists & inhibitors*
  • AMP-Activated Protein Kinases / metabolism
  • Apoptosis / drug effects*
  • Humans
  • Jurkat Cells
  • K562 Cells
  • Leukemia / drug therapy*
  • Leukemia / genetics
  • Leukemia / metabolism
  • Protein Kinase Inhibitors / pharmacology*
  • Pyrazoles / pharmacology*
  • Pyrimidines / pharmacology*
  • Signal Transduction / drug effects
  • Up-Regulation / drug effects
  • bcl-Associated Death Protein / genetics*

Substances

  • BAD protein, human
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • bcl-Associated Death Protein
  • dorsomorphin
  • AMP-Activated Protein Kinases